Geron ends Phase 3 IMpactMF trial of imetelstat in myelofibrosis

what happened

Geron has decided to stop its Phase 3 IMpactMF study of imetelstat in myelofibrosis, according to an SEC filing and a TradingView summary of it. The decision followed a recommendation from an independent Data Monitoring Committee, which concluded the trial was unlikely to reach its primary overall survival endpoint.

The study enrolled 327 adults with intermediate-2 or high-risk myelofibrosis whose disease had relapsed or stopped responding to JAK inhibitors. Reviewers saw no new safety signals that altered the drug's established safety picture or called for extra monitoring.

Geron says it will analyze the collected data and present the results to the scientific community at a later date. The company added that it continues to prioritize growing demand for RYTELO in the U.S. and widening access for eligible patients with lower-risk MDS outside the country.

why it matters

For a biotech company, closing a key late-stage study in a niche oncology area casts doubt on imetelstat's prospects in myelofibrosis and raises the importance of RYTELO sales in MDS. Investors will be waiting for the full data release to judge the study's outcome.

market impact

Geron shares: closing the key trial weakens imetelstat's myelofibrosis outlook, adding pressure on the stock.

• ▼Geron shares pressure down — the main myelofibrosis trial is stopped, weakening the drug's prospects in that indication

tags

instruments